**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
María Lourdes Posadas Martínez; Delfina Cirelli; Florencia De Florio; María Adela Aguirre; María Soledad Saez; Patricia Beatriz Sorroche; Erika Barbara Brulc; Elsa Mercedes Nucifora; Valeria Aliperti; Jimena Vicens; Marcelina Carretero.
Submitting Author: Delfina Cirelli. Hospital Italiano de Buenos Aires. Ciudad Autónoma de Buenos Aires. Argentina.

**Main Body of the Abstract**
Background: Data on the epidemiology of amyloidosis are scarce worldwide, making it difficult to understand its true incidence and mortality.
Objective: To estimate the incidence and mortality rate of systemic amyloidosis in people affiliated to a Medical Care Program in Buenos Aires, Argentina.
Materials & methods: Prospective cohort study. All affiliates to the Medical Care Program of the Hospital Italiano de Buenos Aires, and incident cases and deaths due to amyloidosis from the Institucional Amyloidosis Registry from January 1, 2011, to December 31, 2022, were included. Incidence and mortality rates were reported per million person-year with their respective 95% confidence intervals (95%CI). Crude, standardized, and stratified rates were determined.
Results: During the study period, 1668182 person-year were at risk. The crude incidence rate was 63 (95%CI 52-76) and the crude mortality rate was 31 (95%CI 23-40) cases per million person-years. The ATTR wild-type amyloidosis subtype exhibited the highest rates, followed by AL  amyloidosis. Men were more affected, especially from the age of 70 years onwards. Additionally, an increase in the incidence and mortality rate was observed throughout the period studied. The standardized incidence rate to the US population was 20 (95%CI 15-25) cases per million person-year.
Summary & Conclusion: The results of this study indicate that amyloidosis remains a rare disease but has increased in incidence in recent years, especially in elderly people. This underlines the importance of further research in epidemiology for a better understanding of the pathology and its evolution.



**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
María Lourdes Posadas Martínez; Delfina Cirelli; Florencia De Florio; María Adela Aguirre; María Soledad Saez; Patricia Beatriz Sorroche; Erika Barbara Brulc; Elsa Mercedes Nucifora; Valeria Aliperti; Jimena Vicens; Marcelina Carretero.
Submitting Author: Delfina Cirelli. Hospital Italiano de Buenos Aires. Ciudad Autónoma de Buenos Aires. Argentina.

**Main Body of the Abstract**
**Background:** Data on the epidemiology of amyloidosis are scarce worldwide, making it difficult to understand its true incidence and mortality.
**Objective:** To estimate the incidence and mortality rate of systemic amyloidosis in people affiliated to a Medical Care Program in Buenos Aires, Argentina.
**Materials & methods:** Prospective cohort study. All affiliates to the Medical Care Program of the Hospital Italiano de Buenos Aires, and incident cases and deaths due to amyloidosis from the Institucional Amyloidosis Registry from January 1, 2011, to December 31, 2022, were included. Incidence and mortality rates were reported per million person-year with their respective 95% confidence intervals (95%CI). Crude, standardized, and stratified rates were determined.
**Results:** During the study period, 1668182 person-year were at risk. The crude incidence rate was 63 (95%CI 52-76) and the crude mortality rate was 31 (95%CI 23-40) cases per million person-years. The ATTR wild-type amyloidosis subtype exhibited the highest rates, followed by AL  amyloidosis. Men were more affected, especially from the age of 70 years onwards. Additionally, an increase in the incidence and mortality rate was observed throughout the period studied. The standardized incidence rate to the US population was 20 (95%CI 15-25) cases per million person-year.
**Summary & Conclusion:** The results of this study indicate that amyloidosis remains a rare disease but has increased in incidence in recent years, especially in elderly people. This underlines the importance of further research in epidemiology for a better understanding of the pathology and its evolution.



Epidemiological perspectives of amyloidosis in Argentina: results of an analysis of incidence and mortality in a population affiliated to a Medical Care Program PA110 (#108)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.